2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 476

A Better Understanding of Childhood Sjögren Syndrome: Evaluation of the 2016 Acr/EULAR Classification Criteria for Use in Diagnosing Sjögren Syndrome in Children
Abstract Number: 2845

A Close Relationship between a Novel Visceral Adiposity Index and Bone Microstructure in Female Early Rheumatoid Arthritis Patients: A 1-Year Follow-up Study By HR-pQCT
Abstract Number: 1155

A Collaborative Cardio-Rheumatology Clinic for Primary Prevention of Cardiovascular Diseases – a Descriptive Study
Abstract Number: 299

A Comparison of Persistent Versus Limited Frequent Emergency Department (ED) Utilization Among Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 2757

A Comparison of Pharmacokinetic and Pharmacodynamic Outcomes of Tocilizumab Treatment in Giant Cell Arteritis after Subcutaneous and Intravenous Dosing
Abstract Number: 325

A Comparison of RADAI5 and RAPID3 Disease Measures
Abstract Number: 2152

A Comparison of the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics Classification (SLICC) Criteria to Detect Patients with Systemic Lupus Erythematosus (SLE) in Electronic Health Record (EHR) Data
Abstract Number: 1034

A Conplastic Mice Model of Aging Reveals That Mitochondrial DNA Variation Influences the Process of Joint Deterioration
Abstract Number: 1256

A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors
Abstract Number: 1785

A Data-Driven Approach to Guide Physicians When Considering the Differential Diagnosis of IgG4-Related Disease
Abstract Number: 215

A Decade Earlier- Onset of Symptoms of RA in the Indian (Asian) Cohort Compared to Dutch Cohort: Based on Meteor, a Global Database
Abstract Number: 1800

A Declining Trend in Frequency of Secondary Amyloidosis in Behçet’s Syndrome
Abstract Number: 2439

A Description of Contraception Practices in the Ohio State University Lupus Cohort
Abstract Number: 2913

A Draft Modified Core Domain Set for Patient-Reported Outcomes (PRO) in Patients with Idiopathic Inflammatory Myopathies (IIM): An Omeract Report
Abstract Number: 2508

A First-in-Man Bioelectronic Therapy for Biologic-Refractory Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].